Ibalizumab

N/A

Report date: 2022/05/19 14:20:22
First In Class

Base Information

Drug NameIbalizumab
Drug Alias Name伊巴珠单抗Monoclonal antibody 5A8Ibalizumab-uiyk艾巴利珠单抗Trogarzo +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-CD4Viral fusion proteins inhibitors
TargetsT-cell surface antigen CD4Viral fusion proteins
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/03/06
Country/TerritoryCanadaUnited StatesTaiwan +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesTheratechnologies Inc
Inactive CompaniesTaimed Biologics IncTanox IncTheratechnologies Europe Ltd
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AX23
Related LinksWikipediaKEGG